Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...
Please provide your email address to receive an email when new articles are posted on . If approved, privosegtor would become the first neuroprotective therapy for optic neuropathies. The PIONEER 1 ...
Oculis Holding (OCS) added ~11% on Tuesday after the Swiss drug developer announced the breakthrough therapy designation for its eye disease therapy Privosegtor as a treatment for optic neuritis (ON), ...
ZUG, Switzerland, January 6, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical ...
Hosted on MSN
5 potato chips that are destroying your vision
Potato chips are a popular snack, but certain ingredients and overconsumption habits can affect more than just your waistline — they can also impact your long-term eye health. While an occasional chip ...
FDA alerts and updates on the latest drug and device approvals, recalls, and other regulatory developments in ophthalmology.
Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Somer G. Anderson is CPA, doctor of ...
Primary angle-closure glaucoma can cause blindness. Here, the authors study populations of Asian and European ancestries and find that genetic factors associated with darker irises and being far ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results